ClearPoint Neuro Statistics
Share Statistics
ClearPoint Neuro has 27.58M shares outstanding. The number of shares has increased by 12.01% in one year.
Shares Outstanding | 27.58M |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | 0.64% |
Owned by Institutions (%) | n/a |
Shares Floating | 25.42M |
Failed to Deliver (FTD) Shares | 1.52K |
FTD / Avg. Volume | 0.67% |
Short Selling Information
The latest short interest is 687.56K, so 2.49% of the outstanding shares have been sold short.
Short Interest | 687.56K |
Short % of Shares Out | 2.49% |
Short % of Float | 2.88% |
Short Ratio (days to cover) | 3.36 |
Valuation Ratios
The PE ratio is -7.56 and the forward PE ratio is -18.23.
PE Ratio | -7.56 |
Forward PE | -18.23 |
PS Ratio | 6.97 |
Forward PS | 10.8 |
PB Ratio | 7.89 |
P/FCF Ratio | -11.31 |
PEG Ratio | n/a |
Enterprise Valuation
ClearPoint Neuro Inc. has an Enterprise Value (EV) of 157.87M.
EV / Earnings | -7.15 |
EV / Sales | 6.59 |
EV / EBITDA | -7.52 |
EV / EBIT | -7.03 |
EV / FCF | -10.69 |
Financial Position
The company has a current ratio of 4.87, with a Debt / Equity ratio of 0.49.
Current Ratio | 4.87 |
Quick Ratio | 3.8 |
Debt / Equity | 0.49 |
Total Debt / Capitalization | 32.88 |
Cash Flow / Debt | -1.32 |
Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -1.04% and return on capital (ROIC) is -63.92%.
Return on Equity (ROE) | -1.04% |
Return on Assets (ROA) | -0.52% |
Return on Capital (ROIC) | -63.92% |
Revenue Per Employee | 223.88K |
Profits Per Employee | -206.44K |
Employee Count | 107 |
Asset Turnover | 0.56 |
Inventory Turnover | 1.31 |
Taxes
Income Tax | 0 |
Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 146.07% in the last 52 weeks. The beta is 1.11, so ClearPoint Neuro 's price volatility has been higher than the market average.
Beta | 1.11 |
52-Week Price Change | 146.07% |
50-Day Moving Average | 12.41 |
200-Day Moving Average | 8.79 |
Relative Strength Index (RSI) | 76.84 |
Average Volume (20 Days) | 226.70K |
Income Statement
In the last 12 months, ClearPoint Neuro had revenue of $23.95M and earned -$22.09M in profits. Earnings per share was $-0.9.
Revenue | 23.95M |
Gross Profit | 13.61M |
Operating Income | -22.45M |
Net Income | -22.09M |
EBITDA | -20.99M |
EBIT | -22.45M |
Earnings Per Share (EPS) | -0.9 |
Balance Sheet
The company has $23.14M in cash and $13.94M in debt, giving a net cash position of $9.20M.
Cash & Cash Equivalents | 23.14M |
Total Debt | 13.94M |
Net Cash | 9.20M |
Retained Earnings | -172.46M |
Total Assets | 40.19M |
Working Capital | 26.78M |
Cash Flow
In the last 12 months, operating cash flow was -$13.72M and capital expenditures -$1.05M, giving a free cash flow of -$14.77M.
Operating Cash Flow | -13.72M |
Capital Expenditures | -1.05M |
Free Cash Flow | -14.77M |
FCF Per Share | -0.6 |
Margins
Gross margin is 56.83%, with operating and profit margins of -93.7% and -92.21%.
Gross Margin | 56.83% |
Operating Margin | -93.7% |
Pretax Margin | -92.21% |
Profit Margin | -92.21% |
EBITDA Margin | -87.62% |
EBIT Margin | -93.7% |
FCF Margin | -61.66% |
Dividends & Yields
CLPT does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | -5.87% |
FCF Yield | -3.49% |
Analyst Forecast
The average price target for CLPT is $12, which is -21.7% lower than the current price. The consensus rating is "Strong Buy".
Price Target | $12 |
Price Target Difference | -21.7% |
Analyst Consensus | Strong Buy |
Analyst Count | 2 |
Stock Splits
The last stock split was on Jul 27, 2016. It was a backward split with a ratio of 1:40.
Last Split Date | Jul 27, 2016 |
Split Type | backward |
Split Ratio | 1:40 |
Scores
Altman Z-Score | 17.8 |
Piotroski F-Score | 4 |